AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2020
Oct 2, 2020
33861_dirs_2020-10-01_ec49b13d-d068-4a1d-a444-834dcc31100d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01
Reporting Person: Wahlberg Laura Jean (See Remarks)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.11 | 2026-07-12 | Common Stock (10078) | Direct | |
| Stock Option (Right to Buy) | $2.11 | 2026-10-23 | Common Stock (4150) | Direct | |
| Stock Option (Right to Buy) | $3.72 | 2027-11-27 | Common Stock (3557) | Direct | |
| Stock Option (Right to Buy) | $6.50 | 2029-04-08 | Common Stock (2964) | Direct | |
| Stock Option (Right to Buy) | $4.98 | 2030-07-02 | Common Stock (14821) | Direct | |
| Stock Option (Right to Buy) | $4.98 | 2030-07-02 | Common Stock (2075) | Direct |
Footnotes
F1: 20% of this option vested and became exercisable on May 16, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.
F2: 20% of this option vested and became exercisable on September 1, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.
F3: 20% of this option vested and became exercisable on November 1, 2018, with the remainder vesting in 16 equal quarterly installments thereafter.
F4: 20% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.
F5: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on August 1, 2020.
F6: This option shall vest and become exercisable in 10 equal quarterly installments, with the first installment vesting on September 5, 2020.